CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitiv
published in: Frontiers in Oncology
date of publication: 2015-06-01
main subject: phase II clinical trial, biomarker, ovarian cancer, platinum, olaparib
Cites articles 51
Date
Title
Article - wd:Q35669792